Text Size

Genetic Assessment of the Patients With Metabolic Syndrome (GENMetS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Medical Universtity of Lodz
ClinicalTrials.gov Identifier:
NCT01268696
First received: December 28, 2010
Last updated: July 20, 2011
Last verified: December 2010
History of Changes
  Purpose

Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. The exact mechanisms of the complex pathways of metabolic syndrome are not yet completely known. The pathophysiology is extremely complex and has been only partially elucidated. Most patients are older, obese, sedentary, and have a degree of insulin resistance. Stress can also be a contributing factor. The most important factors are:

weight, genetics, aging, sedentary lifestyle,excess caloric intake. In our study we will assess the role of some polymorphisms in the pathology of metabolic syndrome.


Condition
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Genetic Assessment of the Patients With Metabolic Syndrome in Polish Population

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Medical Universtity of Lodz:

Biospecimen Retention:   Samples With DNA

the blood samples taken into EDTA


Estimated Enrollment: 300
Study Start Date: December 2010
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
control group
healthy volunteers
Metabolic group
Patients with metabolic syndrome

Detailed Description:

Eligibility criteria to the study:

  • patients with metabolic syndrome
  • with written consent
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with metabolic syndrome

Criteria

Inclusion Criteria:

  • patients with metabolic syndrome according to IDF,AHA and NHLBI 2009

Exclusion Criteria:

  • diabetes type 1
  • cancer
  • not consent
  • steroid therapy
  • alcohol or drug abuse
  • chronic inflammatory disease
  • pregnancy or lactation
  • severe hypothyroidism
  • immunosuppressive treatment
  • operation or severe injury during the last month
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01268696

Locations
Poland
Department of medical biotechnology Medical University of Lodz
Lodz, Poland
Sponsors and Collaborators
Medical Universtity of Lodz
Investigators
Study Chair: Tadeusz Pietrucha, prof. Department of medical biotechnology
  More Information

No publications provided

Responsible Party: Department of Medical Biotechnology, Medical University of Lodz
ClinicalTrials.gov Identifier: NCT01268696     History of Changes
Other Study ID Numbers: RNN/202/10/KE
Study First Received: December 28, 2010
Last Updated: July 20, 2011
Health Authority: Poland: Ethics Committee

Keywords provided by Medical Universtity of Lodz:
diabetes
obesity
hypertension
dyslipidemia

Additional relevant MeSH terms:
Metabolic Syndrome X
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 22, 2013